HemapolinCAS# 4267-80-5 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 4267-80-5 | SDF | Download SDF |
PubChem ID | 71752521 | Appearance | Powder |
Formula | C20H32OS | M.Wt | 320.5 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
SMILES | CC12CCC3C(C1CCC2(C)O)CCC4C3(CC5C(C4)S5)C | ||
Standard InChIKey | UPLPHRJJTCUQAY-WIRWPRASSA-N | ||
Standard InChI | InChI=1S/C20H32OS/c1-18-11-17-16(22-17)10-12(18)4-5-13-14(18)6-8-19(2)15(13)7-9-20(19,3)21/h12-17,21H,4-11H2,1-3H3/t12-,13+,14-,15-,16-,17+,18-,19-,20-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Hemapolin Dilution Calculator
Hemapolin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1201 mL | 15.6006 mL | 31.2012 mL | 62.4025 mL | 78.0031 mL |
5 mM | 0.624 mL | 3.1201 mL | 6.2402 mL | 12.4805 mL | 15.6006 mL |
10 mM | 0.312 mL | 1.5601 mL | 3.1201 mL | 6.2402 mL | 7.8003 mL |
50 mM | 0.0624 mL | 0.312 mL | 0.624 mL | 1.248 mL | 1.5601 mL |
100 mM | 0.0312 mL | 0.156 mL | 0.312 mL | 0.624 mL | 0.78 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Dehydrodiconiferyl alcohol
Catalog No.:BCN6878
CAS No.:4263-87-0
- 21,23-Dihydro-23-hydroxy-21-oxozapoterin
Catalog No.:BCN7230
CAS No.:426266-88-8
- TAK-700 salt
Catalog No.:BCC1979
CAS No.:426219-53-6
- TAK-700 (Orteronel)
Catalog No.:BCC2280
CAS No.:426219-18-3
- Luteolin-6-C-glucoside
Catalog No.:BCN4985
CAS No.:4261-42-1
- 8-Hydroxy-5-O-beta-D-glucopyranosylpsoralen
Catalog No.:BCN1443
CAS No.:425680-98-4
- Sotrastaurin (AEB071)
Catalog No.:BCC3857
CAS No.:425637-18-9
- Crocin
Catalog No.:BCN2373
CAS No.:42553-65-1
- Semagacestat (LY450139)
Catalog No.:BCC3610
CAS No.:425386-60-3
- IPA-3
Catalog No.:BCC4978
CAS No.:42521-82-4
- 23-Hydroxylongispinogenin
Catalog No.:BCN7830
CAS No.:42483-24-9
- Isobutyl 4-Hydroxybenzoate
Catalog No.:BCN8412
CAS No.:4247-02-3
- 4-Hydroxy-3-methoxyphenyl O-beta-D-6-O-syringate-glucopyranoside
Catalog No.:BCN1442
CAS No.:426821-85-4
- NS 5806
Catalog No.:BCC7872
CAS No.:426834-69-7
- S-Isopropylisothiourea hydrobromide
Catalog No.:BCC6837
CAS No.:4269-97-0
- Cyproterone Acetate
Catalog No.:BCC3758
CAS No.:427-51-0
- Pedunculoside
Catalog No.:BCN1191
CAS No.:42719-32-4
- 2-Aminophenyl phenyl sulfone
Catalog No.:BCC8554
CAS No.:4273-98-7
- D-Valinol
Catalog No.:BCC2693
CAS No.:4276-09-9
- Magnoflorine Iodide
Catalog No.:BCN2911
CAS No.:4277-43-4
- H-N-Me-Leu-OBzl.TosOH
Catalog No.:BCC3215
CAS No.:42807-66-9
- Shinjulactone L
Catalog No.:BCN7958
CAS No.:4283-49-2
- Catechin 7-xyloside
Catalog No.:BCN5484
CAS No.:42830-48-8
- Flumequine
Catalog No.:BCC5090
CAS No.:42835-25-6
Evaluation of androgenic activity of nutraceutical-derived steroids using mammalian and yeast in vitro androgen bioassays.[Pubmed:21329390]
Anal Chem. 2011 Mar 15;83(6):2065-74.
Androgenic steroids marketed online as nutraceuticals are a growing concern in sport doping. The inability of conventional mass spectrometry (MS)-based techniques to detect structurally novel androgens has led to the development of in vitro androgen bioassays to identify such designer androgens by their bioactivity. The objective of this study was to determine the androgenic bioactivity of novel steroidal compounds isolated from nutraceuticals using both yeast and mammalian cell-based androgen bioassays. We developed two new in vitro androgen bioassays by stably transfecting HEK293 and HuH7 cells with the human androgen receptor (hAR) expression plasmid together with a novel reporter gene vector (enhancer/ARE/SEAP). The yeast beta-galactosidase androgen bioassay was used for comparison. Our new bioassay featuring the enhancer/ARE/SEAP construct (-S) displayed simpler assay format and higher specificity with lower sensitivity compared with the commonly used mouse mammary tumour virus (MMTV)-luciferase. The relative potencies (RP), defined as [EC(50)] of testosterone/[EC(50)] of steroid, of nutraceutical extracts in the yeast, HEK293-S, and HuH7-S, were 34, 333, and 80,000 for Hemapolin; 208, 250, and 80 for Furazadrol; 0.38, 10, and 106 for Oxyguno; 2.7, 0.28, and 15 for Trena; and 4.5, 0.1, and 0.4 for Formadrol, respectively. The wide discrepancies in rank RP of these compounds was reconciled into a consistent potency ranking when the cells were treated with meclofenamic acid, a nonselective inhibitor of steroid metabolizing enzymes. These findings indicate that steroids extracted from nutraceuticals can be converted in vitro into more or less potent androgens in mammalian but not in yeast cells. We conclude that the putative androgenic bioactivity of a new compound may depend on the bioassay cellular format and that mammalian cell bioassays may have an added benefit in screening for proandrogens but sacrifice specificity for sensitivity in quantitation.